Specifically, HER2+ breast cancer cells were inhibited by GSK2830371 either alone or additively with a miR-21 inhibitor43 and breast cancer cells treated with a WIP1 inhibitor were sensitized to doxorubicin and to a MDM2 antagonist32. Here, MDM2 is linked to breast carcinoma.